Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 10/20 | 0.52 |
| ▸ | AGXT | P21549 | 6/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26417660 | 0.86 | ELANE (0.59) | ELANEALOX15HTR2APTGS2 | |
| SCHEMBL17613165 | 0.84 | IDO1 (0.57) | ELANEIDO1AGXTCYP3A4 | |
| Hydrochloric Acid SCHEMBL20168290 | 0.82 | IDO1 (0.58) | ELANEIDO1AGXTCYP3A4 | |
| SCHEMBL27768096 | 0.82 | ELANE (0.59) | ELANEALOX15PTGS2 | |
| SCHEMBL20340729 | 0.81 | ELANE (0.54) | ELANEALOX15HTR2APTGS2 | |
| SCHEMBL21795326 | 0.81 | ELANE (0.79) | ELANEALOX15PTGS2 | |
| SCHEMBL19925263 | 0.80 | ELANE (0.61) | ELANEALOX15HTR2APTGS2 | |
| SCHEMBL14116625 | 0.80 | ELANE (0.61) | ELANEALOX15PTGS2 | |
| SCHEMBL11295876 | 0.80 | ELANE (0.61) | ELANEALOX15PTGS2 | |
| SCHEMBL10585377 | 0.79 | ELANE (0.59) | ELANEALOX15HTR2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866394-B2 | Prodrugs of hydroxamate-based GCPII inhibitors | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-01-09 | — | — | US | disclosed |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2021-11-18 | — | — | US | disclosed |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2019-11-21 | — | — | US | disclosed |
| WO-2018094334-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | GPI, TPI1, HPGDS | ELANE 919/4885IDO1 2011/4885AGXT 165/4885 |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | TPI1, HPGDS, GPI | ELANE 1159/4885IDO1 1935/4885AGXT 271/4885 |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | GLS, HPGDS, GPI | ELANE 715/4885IDO1 2215/4885AGXT 186/4885 |
| US-11866394-B2 | Prodrugs of hydroxamate-based GCPII inhibitors | TPI1, HPGDS, GPI | ELANE 1159/4885IDO1 1935/4885AGXT 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.